Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;27(3):1331-1338.
doi: 10.1038/s41380-021-01367-9. Epub 2021 Nov 4.

Recognizing the importance of childhood maltreatment as a critical factor in psychiatric diagnoses, treatment, research, prevention, and education

Affiliations
Review

Recognizing the importance of childhood maltreatment as a critical factor in psychiatric diagnoses, treatment, research, prevention, and education

Martin H Teicher et al. Mol Psychiatry. 2022 Mar.

Abstract

Childhood maltreatment is the most important preventable risk factor for psychiatric disorders. Maltreated individuals typically develop psychiatric disorders at an earlier age, have a more pernicious course, more comorbidities, greater symptom severity, and respond less favorably to treatments than non-maltreated individuals with the same primary DSM-5 diagnosis. Furthermore, maltreated individuals have alterations in stress-susceptible brain regions, hypothalamic-pituitary-adrenal response, and inflammatory marker levels not discernible in their non-maltreated counterparts. Hence, maltreated and non-maltreated individuals with the same primary DSM-5 diagnoses appear to be clinically and neurobiologically distinct. The failure to embody this distinction in DSM-5 has interfered with our ability to discover novel treatments, to recommend currently available treatments most likely to be efficacious, and has been a largely unrecognized confound that has thwarted our ability to identify the biological basis for major psychiatric disorders. Incorporating this distinction into DSM will help transform this sign and symptom-based classification system to a more etiologically informed nosology. We discuss several diagnostic alternatives and recommend the inclusion of a Developmental Trauma Disorder diagnosis for severely dysregulated individuals, of all ages, with numerous comorbidities, who experienced interpersonal victimization and disruptions in attachment, such as emotional maltreatment or neglect. For less severely affected maltreated individuals, we suggest using conventional diagnostic categories, such as major depression, but with an essential modifier indicating a history of childhood maltreatment, or early life stress, to delineate the ecophenotypic variant. Implementing this strategy should improve our ability to effectively diagnose and treat individuals with psychiatric disorders and to accelerate discovery.

PubMed Disclaimer

Conflict of interest statement

MHT has created rating scales to retrospectively assess type and timing of exposure to CM [16] but there is no financial conflict as he has placed these scales into the public domain. MHT has also received research or consulting fees (last 12 months) from the NIH, Interactive Metronome™, Brain Balance Centers™, the ANS Foundation, and MindLight™. MHT is on the Scientific Advisory Board for the Juvenile Bipolar Research Foundation and member of the Board of Children, Youth and Families at the National Academies of Sciences, Engineering and Medicine and a member of the Board of Directors of the Trauma Research Foundation and the Kahn Family Foundation. MHT has been awarded 19 US Patents, none of which are relevant to this article. CBN has received grant support from the NIH. During the last 12 months, he has consulted to ANeuroTech (division of Anima BV), Signant Health, Sunovion Pharmaceuticals, Inc., Janssen Research & Development LLC, Magstim, Inc., Navitor Pharmaceuticals, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Acadia Pharmaceuticals, Axsome, Sage, BioXcel Therapeutics, Silo Pharma, XW Pharma, Neuritek, Engrail Therapeutics, and Corcept Therapeutics Pharmaceuticals Company. CBN is a stockholder in Xhale, Seattle Genetics, Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, and EMA Wellness; he is on the Scientific Advisory Board for ANeuroTech (division of Anima BV), Brain and Behavior Research Foundation (BBRF), Anxiety and Depression Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Magnolia CNS; and he is on the Board of Directors for Gratitude America, ADAA, and Xhale Smart, Inc. CBN holds two patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1) and Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2). He is not a part of any Speakers Bureau. JBG has no potential conflicts of interest to disclose.

References

    1. Lippard ETC, Nemeroff CB. The devastating clinical consequences of child abuse and neglect: increased disease vulnerability and poor treatment response in mood disorders. Am J Psychiatry. 2020;177:20–36. doi: 10.1176/appi.ajp.2019.19010020. - DOI - PMC - PubMed
    1. Teicher MH, Samson JA. Childhood maltreatment and psychopathology: a case for ecophenotypic variants as clinically and neurobiologically distinct subtypes. Am J Psychiatry. 2013;170:1114–33. doi: 10.1176/appi.ajp.2013.12070957. - DOI - PMC - PubMed
    1. Williams LM, Debattista C, Duchemin AM, Schatzberg AF, Nemeroff CB. Childhood trauma predicts antidepressant response in adults with major depression: data from the randomized international Study to Predict Optimized Treatment for Depression. Transl Psychiatry. 2016;6:e799. doi: 10.1038/tp.2016.61. - DOI - PMC - PubMed
    1. Teicher MH, Samson JA, Anderson CM, Ohashi K. The effects of childhood maltreatment on brain structure, function and connectivity. Nat Rev Neurosci. 2016;17:652–66. doi: 10.1038/nrn.2016.111. - DOI - PubMed
    1. American Psychiatric Association. Diagnostic and Statistical Manual of mental disorders. 5th ed. Washington DC: American Psychiatric Press; 2013.

Publication types